Reclassification of Good-Risk Seminoma: Prognostic Factors, Novel Biomarkers and Implications For Clinical Management

Casadei, Chiara; Schepisi, Giuseppe; Menna, Cecilia; Chovanec, Michal; Gurioli, Giorgia; Gallà, Valentina; Altavilla, Amelia; Marcellini, Massimo; Bellia, S.R.; Lolli, Cristian; Mego, Michal; Rosti, Giovanni; Giorgi, Ugo De

doi:10.2217/fon-2018-0850

Cited by 4 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Matching treatment intent to the extent of disease might be straightforward in some scenarios, such as curative intent in the early disease setting, but not in others. For example, the development of multiple lung metastases would make the intent of subsequent SACT palliative in a patient with breast cancer since advanced breast cancer is believed to be incurable; 2 however, if the same clinical scenario of multiple lung metastases was seen in a patient with seminoma, the intent may still be curative, 33 given the excellent chemosensitivity of this type of cancer. If a patient with a limited number of liver metastases receives preoperative chemotherapy followed by complete resection, some clinicians and trial protocols would not count this as a 'line' of SACT in the case of a colonic primary; by contrast, chemotherapy for treating liver metastases would count as a LoT for a patient with breast cancer.…”

Section: A Proposed Systematic and Comprehensive Framework To Determine Lot Terminology And Definitionsmentioning

confidence: 99%

Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework

Saini

Twelves

2021

Br J Cancer

View full text Add to dashboard Cite

The complexity of neoplasia and its treatment are a challenge to the formulation of general criteria that are applicable across solid cancers. Determining the number of prior lines of therapy (LoT) is critically important for optimising future treatment, conducting medication audits, and assessing eligibility for clinical trial enrolment. Currently, however, no accepted set of criteria or definitions exists to enumerate LoT. In this article, we seek to open a dialogue to address this challenge by proposing a systematic and comprehensive framework to determine LoT uniformly across solid malignancies. First, key terms, including LoT and ‘clinical progression of disease’ are defined. Next, we clarify which therapies should be assigned a LoT, and why. Finally, we propose reporting LoT in a novel and standardised format as LoT N (CLoT + PLoT), where CLoT is the number of systemic anti-cancer therapies (SACT) administered with curative intent and/or in the early setting, PLoT is the number of SACT given with palliative intent and/or in the advanced setting, and N is the sum of CLoT and PLoT. As a next step, the cancer research community should develop and adopt standardised guidelines for enumerating LoT in a uniform manner.

show abstract

Section: A Proposed Systematic and Comprehensive Framework To Determine Lot Terminology And Definitionsmentioning

confidence: 99%

Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework

Saini

Twelves

2021

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…A recent review made the following conclusion: "Having systematically reviewed the available literature, we found surprisingly little evidence to guide optimal testing with biomarkers (AFP, hCG and LDH) routinely used during follow-up for testicular cancer recurrence" [65]. Due to all these reasons, there is still a substantial effort to find novel biomarkers which are more reliable for example, for disease prognosis [66] or diagnostics (DNA methylation, microRNAs, proteins) [17,[67][68][69][70].…”

Section: Other Tc Biomarkersmentioning

confidence: 99%

Glycan Analysis as Biomarkers for Testicular Cancer

et al. 2019

View full text Add to dashboard Cite

The U.S. Preventive Services Task Force does not recommend routine screening for testicular cancer (TC) in asymptomatic men, essentially because serological testicular cancer (TC) biomarkers are not reliable. The main reason is that two of the most important TC biomarkers, α-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are not produced solely due to TC. Moreover, up to 40% of patients with TC do not have elevated serological biomarkers, which is why serial imaging with CT is the chief means of monitoring progress. On the other hand, exposure to radiation can lead to an increased risk of secondary malignancies. This review provides the first comprehensive account of the applicability of protein glycoprofiling as a promising biomarker for TC with applications in disease diagnostics, monitoring and recurrence evaluation. The review first deals with the description and classification of TC. Secondly, the limitations of current TC biomarkers such as hCG, AFP and lactate dehydrogenase are provided together with an extensive overview of the glycosylation of hCG and AFP related to TC. The final part of the review summarises the potential of glycan changes on either hCG and AFP as TC biomarkers for diagnostics and prognostics purposes, and for disease recurrence evaluation. Finally, an analysis of glycans in serum and tissues as TC biomarkers is also provided.

show abstract

“…1 However, they represent 11% of the cancers diagnosed in adolescent males and are the most common solid tumors in adult men between the ages of 20 to 35. 2 And pure seminoma accounts for around 50% of all TGCTs. 2 Cryptorchidism is a very common dysmorphia of the male urogenital system, affecting 2-4% of male infants.…”

Section: Introductionmentioning

confidence: 99%

“…2 And pure seminoma accounts for around 50% of all TGCTs. 2 Cryptorchidism is a very common dysmorphia of the male urogenital system, affecting 2-4% of male infants. [3][4][5] As we all know, cryptorchidism is one of the risk factors of testicular cancer, with approximately 10% of testicular cancer occurring in this setting.- 1,2,5 Men with a previous history of cryptorchidism have a higher risk of suffering testicular cancers, which appears to be 5-10 times more common than in normal people.…”

Section: Introductionmentioning

confidence: 99%

“…2 Cryptorchidism is a very common dysmorphia of the male urogenital system, affecting 2-4% of male infants. [3][4][5] As we all know, cryptorchidism is one of the risk factors of testicular cancer, with approximately 10% of testicular cancer occurring in this setting.- 1,2,5 Men with a previous history of cryptorchidism have a higher risk of suffering testicular cancers, which appears to be 5-10 times more common than in normal people. 2,6,7 To our knowledge, there were several studies [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15] describing the relationship between cryptorchidism and testicular cancer, but no one reported whether cryptorchidism affects the clinical stage of testicular cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Evaluating the Effect of Cryptorchidism on Clinical Stage of Testicular Seminoma</p>

Wang¹,

Chen²,

Qiu³

et al. 2020

CMAR

View full text Add to dashboard Cite

To study the effect of cryptorchidism on clinical stage (CS) of testicular seminoma (TS). Patients and Methods: In the Surveillance Epidemiology and End Results (SEER) database (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016), people with TS were enrolled in our research. Multivariable logistic regression models were constructed to compare the impact of cryptorchidism on CS. Results: This research was based on the registry information of 12,991 TS patients. All patients with a median age of 36 (13-107) years were pathologically diagnosed with orchiectomy or needle biopsy specimens. Patients with CS I, II, and III TS accounted for 70.68% (n = 9182), 8.30% (n = 1078), and 5.75% (n = 747) of all patients, respectively; still there were 15.27% (n = 1984) of patients whose CS could not be identified or was not available. Among all included patients, 43.45% (n = 5644) of them had normal testis, 2.93% (n = 272) had cryptorchidism, and the primary site of 54.46% (n = 7075) of patients' testis was unavailable. According to our study, patients with cryptorchidism were more likely to suffer advanced CS [OR=1.14, 95% CI (1.01-1.28), p=0.0407]. Furthermore, this effect became more remarkable after adjusting for other factors including age, region, marital status, race, year of diagnosis and laterality [OR=1.23, 95% CI (1.13-1.32), p<0.0001]. Conclusion:According to this study, TS patients with cryptorchidism would be at a higher risk of suffering advanced cancer than patients with normal testis. It demonstrates that surgical correction for cryptorchidism should be timely, and specific management should be conducted on this kind of TS patients.

show abstract

Reclassification of Good-Risk Seminoma: Prognostic Factors, Novel Biomarkers and Implications For Clinical Management

Cited by 4 publications

References 37 publications

Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework

Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework

Glycan Analysis as Biomarkers for Testicular Cancer

<p>Evaluating the Effect of Cryptorchidism on Clinical Stage of Testicular Seminoma</p>

Contact Info

Product

Resources

About